ASO Author Reflections: Limited Survival Benefit from Neoadjuvant Chemotherapy in ER+/HER2- Breast Cancer.
Uložené v:
| Názov: | ASO Author Reflections: Limited Survival Benefit from Neoadjuvant Chemotherapy in ER+/HER2- Breast Cancer. |
|---|---|
| Autori: | Zou Y; Department of Breast Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China., Bian L; Department of Breast Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhang H; Department of Breast Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China., Tang H; Department of Breast Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China. tanghl@sysucc.org.cn., Peng C; State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. pengchengchengdu@126.com., Wang J; Department of Breast Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China. wangjin1@sysucc.org.cn. |
| Zdroj: | Annals of surgical oncology [Ann Surg Oncol] 2025 Sep; Vol. 32 (9), pp. 6687-6688. Date of Electronic Publication: 2025 May 17. |
| Spôsob vydávania: | Journal Article |
| Jazyk: | English |
| Informácie o časopise: | Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: In Process; MEDLINE |
| Imprint Name(s): | Publication: 2005- : New York, NY : Springer Original Publication: New York, NY : Raven Press, c1994- |
| Abstrakt: | Competing Interests: Disclosure: The authors have no conflict of interest to declare. |
| References: | Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021;375:e066381. Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39(13):1485–505. Wang J, Yang B, Bian L, et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in ER+/HER2-locally advanced breast cancer. Ann Surg Oncol. 2025. https://doi.org/10.1245/s10434-025-17297-7 . (PMID: 10.1245/s10434-025-17297-7) Sella T, Weiss A, Mittendorf EA, King TA, Pilewskie M, Giuliano AE, et al. Neoadjuvant endocrine therapy in clinical practice: a review. JAMA Oncol. 2021;7(11):1700–8. Goldbach MM, Burkbauer L, Bharani T, Williams AD, Keele L, Rothman J, et al. Effectiveness of a short duration of neoadjuvant endocrine therapy in patients with HR+ breast cancer-An NCDB analysis (2004–2016). Ann Surg Oncol. 2021;28(13):8651–62. Cantini L, Trapani D, Guidi L, Boscolo Bielo L, Scafetta R, Koziej M, et al. Neoadjuvant therapy in hormone receptor-positive/HER2-negative breast cancer. Cancer Treat Rev. 2024;123:102669. |
| Entry Date(s): | Date Created: 20250517 Latest Revision: 20250805 |
| Update Code: | 20250805 |
| DOI: | 10.1245/s10434-025-17408-4 |
| PMID: | 40382451 |
| Databáza: | MEDLINE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Competing Interests: Disclosure: The authors have no conflict of interest to declare. |
|---|---|
| ISSN: | 1534-4681 |
| DOI: | 10.1245/s10434-025-17408-4 |